{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:53:43Z","timestamp":1793393623807,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Sichuan Provincial Science and Technology Department","award":["2023YFS0042"],"award-info":[{"award-number":["2023YFS0042"]}]},{"name":"the Health Commission of Sichuan Provincial","award":["24LCYJZD04"],"award-info":[{"award-number":["24LCYJZD04"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82571515"],"award-info":[{"award-number":["82571515"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00228-026-04173-w","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:57:36Z","timestamp":1788832656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent research progress on the mechanisms of clopidogrel resistance"],"prefix":"10.1007","volume":"82","author":[{"given":"Chunrong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hewei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yapeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quandan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"4173_CR1","doi-asserted-by":"publisher","unstructured":"Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL (2019) Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association. Stroke 50(12):e344\u2013e418. https:\/\/doi.org\/10.1161\/str.0000000000000211","DOI":"10.1161\/str.0000000000000211"},{"key":"4173_CR2","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O\u2019Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American, ACC\/AHA\/ACP\/AATS (2016) \/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 134 (10): e123-155 DOI 10.1161\/cir.0000000000000404IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1IF: 41.3 Q1 B1"},{"issue":"3","key":"4173_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, J\u00fcni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39(3):213\u2013260. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"key":"4173_CR4","doi-asserted-by":"publisher","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith SC Jr., Turan TN, Williams LS (2021) 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association. Stroke 52(7):e364\u2013e467. https:\/\/doi.org\/10.1161\/str.0000000000000375","DOI":"10.1161\/str.0000000000000375"},{"key":"4173_CR5","doi-asserted-by":"publisher","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL, de Lemos JA, DeWald TA, Elgendy IY, Feldman DN, Goyal A, Isiadinso I, Menon V, Morrow DA, Mukherjee D, Platz E, Promes SB, Sandner S, Sandoval Y, Schunder R, Shah B, Stopyra JP, Talbot AW, Taub PR, Williams MS (2025) 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 151(13):e771\u2013e862. https:\/\/doi.org\/10.1161\/cir.0000000000001309","DOI":"10.1161\/cir.0000000000001309"},{"key":"4173_CR6","doi-asserted-by":"publisher","unstructured":"Cencer S, Packard L, Davis A, Ahrar A, Miller M, Khan N, Wees N, Min J (2025) Prevalence of Aspirin or Clopidogrel Pharmacological Resistance in Ischemic Stroke: A Step Toward Precision Medicine. CNS Neurosci Ther 31(3):e70343. https:\/\/doi.org\/10.1111\/cns.70343","DOI":"10.1111\/cns.70343"},{"key":"4173_CR7","doi-asserted-by":"publisher","unstructured":"Mo Y, Lu Y, Guo F, Wu A, Weng Y (2023) Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China. Front Cardiovasc Med 10:1020593. https:\/\/doi.org\/10.3389\/fcvm.2023.1020593","DOI":"10.3389\/fcvm.2023.1020593"},{"key":"4173_CR8","doi-asserted-by":"publisher","unstructured":"Giantini A, Timan IS, Dharma R, Sukmawan R, Setiabudy R, Alwi I, Harahap AR, Listiyaningsih E, Partakusuma LG, Tansir AR, Sahar W, Hidayat R (2022) The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention. Front Cardiovasc Med 9:1027892. https:\/\/doi.org\/10.3389\/fcvm.2022.1027892","DOI":"10.3389\/fcvm.2022.1027892"},{"key":"4173_CR9","doi-asserted-by":"publisher","unstructured":"Duconge J, Santiago E, Hernandez-Suarez DF, Moner\u00f3 M, L\u00f3pez-Reyes A, Rosario M, Renta JY, Gonz\u00e1lez P, Ileana Fern\u00e1ndez-Morales L, Antonio V\u00e9lez-Figueroa L, Arce O, Mar\u00edn-Maldonado F, Nu\u00f1ez H, Melin K, Scott SA, Rua\u00f1o G (2021) Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach. Clin Transl Sci 14(6):2254\u20132266. https:\/\/doi.org\/10.1111\/cts.13124","DOI":"10.1111\/cts.13124"},{"issue":"19","key":"4173_CR10","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.26355\/eurrev_202110_26885","volume":"25","author":"NM El-Khodary","year":"2021","unstructured":"El-Khodary NM, El-Behery AM, El-Askary NA, Donia HM, Omran GA (2021) The correlation between platelet responsiveness to clopidogrel and CYP2C19 polymorphism in patients with peripheral vascular disease. Eur Rev Med Pharmacol Sci 25(19):6065\u20136076. https:\/\/doi.org\/10.26355\/eurrev_202110_26885","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4173_CR11","doi-asserted-by":"publisher","unstructured":"Jafrin S, Naznin NE, Reza MS, Aziz MA, Islam MS (2021) Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis. Eur J Intern Med 90:49\u201365. https:\/\/doi.org\/10.1016\/j.ejim.2021.05.022","DOI":"10.1016\/j.ejim.2021.05.022"},{"issue":"6","key":"4173_CR12","doi-asserted-by":"publisher","first-page":"107684","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107684","volume":"33","author":"Y Wu","year":"2024","unstructured":"Wu Y, Shen H, Cai B, Chen C, Yin Q, Zhao Y, Zhou G (2024) Factors associated with clopidogrel resistance and clinical outcomes in ischemic cerebrovascular disease: A retrospective study. J Stroke Cerebrovasc Dis 33(6):107684. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2024.107684","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"3\u20134","key":"4173_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000521531","volume":"107","author":"O Baturina","year":"2022","unstructured":"Baturina O, Andreev D, Fedina L, Mirzaev K, Ivashchenko D, Ryzhikova K, Grishina E, Bochkov P, Shevchenko R, Sychev D (2022) Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation. Pharmacology 107(3\u20134):216\u2013226. https:\/\/doi.org\/10.1159\/000521531","journal-title":"Pharmacology"},{"issue":"1","key":"4173_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/dmd.109.029132","volume":"38","author":"M Kazui","year":"2010","unstructured":"Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38(1):92\u201399. https:\/\/doi.org\/10.1124\/dmd.109.029132","journal-title":"Drug Metab Dispos"},{"issue":"20","key":"4173_CR15","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1001\/jama.2011.1703","volume":"306","author":"JL Mega","year":"2011","unstructured":"Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS (2011) Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306(20):2221\u20132228. https:\/\/doi.org\/10.1001\/jama.2011.1703","journal-title":"JAMA"},{"issue":"8","key":"4173_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.2020.12443","volume":"324","author":"NL Pereira","year":"2020","unstructured":"Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C (2020) Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA 324(8):761\u2013771. https:\/\/doi.org\/10.1001\/jama.2020.12443","journal-title":"JAMA"},{"issue":"27","key":"4173_CR17","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","volume":"385","author":"Y Wang","year":"2021","unstructured":"Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC, Li H, Bath PM, Dong Q, Xu A, Jing J, Lin J, Niu S, Wang Y, Zhao X, Li Z, Jiang Y, Li W, Liu L, Xu J, Chang L, Wang L, Zhuang X, Zhao J, Feng Y, Man H, Li G, Wang B (2021) Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. N Engl J Med 385(27):2520\u20132530. https:\/\/doi.org\/10.1056\/NEJMoa2111749","journal-title":"N Engl J Med"},{"issue":"6","key":"4173_CR18","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/cts.12830","volume":"13","author":"Y Ionova","year":"2020","unstructured":"Ionova Y, Ashenhurst J, Zhan J, Nhan H, Kosinski C, Tamraz B, Chubb A (2020) CYP2C19 Allele Frequencies in Over 2.2 Million Direct-to-Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System. Clin Transl Sci 13(6):1298\u20131306. https:\/\/doi.org\/10.1111\/cts.12830","journal-title":"Clin Transl Sci"},{"issue":"5","key":"4173_CR19","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","volume":"112","author":"CR Lee","year":"2022","unstructured":"Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, Kisor DF, Limdi NA, Lee YM, Scott SA, Hulot JS, Roden DM, Gaedigk A, Caudle KE, Klein TE, Johnson JA, Shuldiner AR (2022) Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther 112(5):959\u2013967. https:\/\/doi.org\/10.1002\/cpt.2526","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4173_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/fpc.0000000000000469","volume":"32","author":"ZO Ali","year":"2022","unstructured":"Ali ZO, Bader L, Mohammed S, Arafa S, Arabi A, Cavallari L, Langaee T, Mraiche F, Rizk N, Awaisu A, Shahin MH, Elewa H (2022) Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation. Pharmacogenet Genomics 32(5):183\u2013191. https:\/\/doi.org\/10.1097\/fpc.0000000000000469","journal-title":"Pharmacogenet Genomics"},{"key":"4173_CR21","doi-asserted-by":"publisher","unstructured":"Mirzaev KB, Osipova DV, Kitaeva EJ, Shprakh VV, Abdullaev SP, Andreev DA, Mumladze RB, Sychev DA (2019) Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metab Pers Ther 34(3). https:\/\/doi.org\/10.1515\/dmpt-2018-0039","DOI":"10.1515\/dmpt-2018-0039"},{"issue":"1","key":"4173_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0b013e32835aa8a2","volume":"23","author":"JP Lewis","year":"2013","unstructured":"Lewis JP, Horenstein RB, Ryan K, O\u2019Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR (2013) The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics 23(1):1\u20138. https:\/\/doi.org\/10.1097\/FPC.0b013e32835aa8a2","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"4173_CR23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1124\/jpet.112.201640","volume":"344","author":"HJ Zhu","year":"2013","unstructured":"Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS (2013) Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther 344(3):665\u2013672. https:\/\/doi.org\/10.1124\/jpet.112.201640","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"4173_CR24","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1080\/14740338.2020.1836152","volume":"19","author":"M Biswas","year":"2020","unstructured":"Biswas M, Rahaman S, Biswas TK, Ibrahim B (2020) Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: A systematic review and meta-analysis. Expert Opin Drug Saf 19(12):1605\u20131616. https:\/\/doi.org\/10.1080\/14740338.2020.1836152","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"4173_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.gene.2014.12.051","volume":"558","author":"XQ Wang","year":"2015","unstructured":"Wang XQ, Shen CL, Wang BN, Huang XH, Hu ZL, Li J (2015) Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene 558(2):200\u2013207. https:\/\/doi.org\/10.1016\/j.gene.2014.12.051","journal-title":"Gene"},{"issue":"2","key":"4173_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.14744\/AnatolJCardiol.2017.8097","volume":"19","author":"ZL Zhuo","year":"2018","unstructured":"Zhuo ZL, Xian HP, Long Y, Liu C, Sun YY, Ma YT, Gao H, Zhao JZ, Zhao XT (2018) Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. Anatol J Cardiol 19(2):123\u2013129. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2017.8097","journal-title":"Anatol J Cardiol"},{"key":"4173_CR27","doi-asserted-by":"publisher","first-page":"889473","DOI":"10.3389\/fphar.2022.889473","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen L, Zheng C, Hao M, Gao P, Zhao M, Cao Y, Ma L (2022) Association of ABCC2 polymorphism with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention. Front Pharmacol 13:889473. https:\/\/doi.org\/10.3389\/fphar.2022.889473","journal-title":"Front Pharmacol"},{"issue":"5","key":"4173_CR28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bcpt.12703","volume":"120","author":"AD Luchessi","year":"2017","unstructured":"Luchessi AD, Concheiro M, Germano JF, Silbiger VN, Bortolin RH, Cruz A, Quintela O, Brion M, Carracedo A, I\u00f1iguez A, Bravo M, L\u00f3pez-Rivadulla M, Hirata RD, Sousa AG, Hirata MH (2017) ABCC3 Polymorphisms and mRNA Expression Influence the Concentration of a Carboxylic Acid Metabolite in Patients on Clopidogrel and Aspirin Therapy. Basic Clin Pharmacol Toxicol 120(5):466\u2013474. https:\/\/doi.org\/10.1111\/bcpt.12703","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"4173_CR29","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cpt.589","volume":"101","author":"WP Zhong","year":"2017","unstructured":"Zhong WP, Wu H, Chen JY, Li XX, Lin HM, Zhang B, Zhang ZW, Ma DL, Sun S, Li HP, Mai LP, He GD, Wang XP, Lei HP, Zhou HK, Tang L, Liu SW, Zhong SL (2017) Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel. Clin Pharmacol Ther 101(6):791\u2013802. https:\/\/doi.org\/10.1002\/cpt.589","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"4173_CR30","doi-asserted-by":"publisher","first-page":"e6553","DOI":"10.1097\/md.0000000000006553","volume":"96","author":"M Li","year":"2017","unstructured":"Li M, Wang H, Xuan L, Shi X, Zhou T, Zhang N, Huang Y (2017) Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. Med (Baltim) 96(14):e6553. https:\/\/doi.org\/10.1097\/md.0000000000006553","journal-title":"Med (Baltim)"},{"issue":"5","key":"4173_CR31","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1002\/jcla.70003","volume":"39","author":"H Ta Anh","year":"2025","unstructured":"Ta Anh H, Nguyen Duy T, Bui Duc T, Hoang Van T, Nguyen Oanh O, Luong Cong T, Truong Dinh C (2025) Association of P2RY12 Gene Variants and Non-Genetic Factors With Clopidogrel Responsiveness in Vietnamese Patients After Percutaneous Coronary Intervention: A Cross-Sectional Study. J Clin Lab Anal 39(5):e70003. https:\/\/doi.org\/10.1002\/jcla.70003","journal-title":"J Clin Lab Anal"},{"issue":"1","key":"4173_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12872-022-02988-w","volume":"22","author":"YJ Zhang","year":"2022","unstructured":"Zhang YJ, Li DJ, Li ZY, Hu XL, Li H, Ma QL, Chen XP (2022) Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease. BMC Cardiovasc Disord 22(1):575. https:\/\/doi.org\/10.1186\/s12872-022-02988-w","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"4173_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000457947","volume":"137","author":"G Siasos","year":"2017","unstructured":"Siasos G, Oikonomou E, Vavuranakis M, Kokkou E, Mourouzis K, Tsalamandris S, Zaromitidou M, Kioufis S, Tsigkou V, Deftereos S, Stefanadis C, Tousoulis D (2017) Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. Cardiology 137(2):104\u2013113. https:\/\/doi.org\/10.1159\/000457947","journal-title":"Cardiology"},{"issue":"5","key":"4173_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.17116\/terarkh201789574-78","volume":"89","author":"EF Muslimova","year":"2017","unstructured":"Muslimova EF, Afanasiev SA, Rebrova TY, Sergienko TN, Repin AN (2017) [Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy]. Ter Arkh 89(5):74\u201378. https:\/\/doi.org\/10.17116\/terarkh201789574-78","journal-title":"Ter Arkh"},{"issue":"7","key":"4173_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/1076029616648408","volume":"23","author":"X Yi","year":"2017","unstructured":"Yi X, Wang Y, Lin J, Cheng W, Zhou Q, Wang C (2017) Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. Clin Appl Thromb Hemost 23(7):761\u2013768. https:\/\/doi.org\/10.1177\/1076029616648408","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"4173_CR36","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/cpt.3552","volume":"117","author":"G Yang","year":"2025","unstructured":"Yang G, Alarcon C, Chanfreau C, Lee NH, Friedman P, Nutescu E, Tuck M, O\u2019Brien T, Gong L, Klein TE, Chang KM, Tsao PS, Meltzer DO, Lynch JA, Tuteja S, Perera MA (2025) Investigation of Genomic and Transcriptomic Risk Factors of Clopidogrel Response in African Americans. Clin Pharmacol Ther 117(5):1313\u20131324. https:\/\/doi.org\/10.1002\/cpt.3552","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4173_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/cpt.401","volume":"100","author":"SA Scott","year":"2016","unstructured":"Scott SA, Collet JP, Baber U, Yang Y, Peter I, Linderman M, Sload J, Qiao W, Kini AS, Sharma SK, Desnick RJ, Fuster V, Hajjar RJ, Montalescot G, Hulot JS (2016) Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clin Pharmacol Ther 100(3):287\u2013294. https:\/\/doi.org\/10.1002\/cpt.401","journal-title":"Clin Pharmacol Ther"},{"key":"4173_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12933-016-0362-0","volume":"15","author":"D Zhang","year":"2016","unstructured":"Zhang D, Zhang X, Liu D, Liu T, Cai W, Yan C, Han Y (2016) Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus. Cardiovasc Diabetol 15:50. https:\/\/doi.org\/10.1186\/s12933-016-0362-0","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"4173_CR39","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41401-018-0178-4","volume":"40","author":"YB Chen","year":"2019","unstructured":"Chen YB, Zhou ZY, Li GM, Xiao CX, Yu WB, Zhong SL, Cai YF, Jin J, Huang M (2019) Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients. Acta Pharmacol Sin 40(6):762\u2013768. https:\/\/doi.org\/10.1038\/s41401-018-0178-4","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"4173_CR40","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/00498254.2017.1372648","volume":"48","author":"KE Burns","year":"2018","unstructured":"Burns KE, Shepherd P, Finlay G, Tingle MD, Helsby NA (2018) Indirect regulation of CYP2C19 gene expression via DNA methylation. Xenobiotica 48(8):781\u2013792. https:\/\/doi.org\/10.1080\/00498254.2017.1372648","journal-title":"Xenobiotica"},{"issue":"2","key":"4173_CR41","doi-asserted-by":"publisher","first-page":"e00738","DOI":"10.1002\/prp2.738","volume":"9","author":"R Sukmawan","year":"2021","unstructured":"Sukmawan R, Hoetama E, Suridanda Danny S, Giantini A, Listiyaningsih E, Gilang Rejeki V, Aziz Alkatiri A, Firdaus I (2021) Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Pharmacol Res Perspect 9(2):e00738. https:\/\/doi.org\/10.1002\/prp2.738","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"4173_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.31083\/ph.2015.4756","volume":"70","author":"J Yang","year":"2015","unstructured":"Yang J, Zhou JS, Zhao YX, Yang ZH, Zhao HD, Zhang YD, Zou JJ (2015) ABCB1 hypomethylation is associated with decreased antiplatelet effects of clopidogrel in Chinese ischemic stroke patients. Pharmazie 70(2):97\u2013102","journal-title":"Pharmazie"},{"issue":"3","key":"4173_CR43","doi-asserted-by":"publisher","first-page":"e0174511","DOI":"10.1371\/journal.pone.0174511","volume":"12","author":"J Su","year":"2017","unstructured":"Su J, Yu Q, Zhu H, Li X, Cui H, Du W, Ji L, Tong M, Zheng Y, Xu H, Zhang J, Zhu Y, Xia Y, Liu T, Yao Q, Yang J, Chen X, Yu J (2017) The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. PLoS ONE 12(3):e0174511. https:\/\/doi.org\/10.1371\/journal.pone.0174511","journal-title":"PLoS ONE"},{"key":"4173_CR44","doi-asserted-by":"publisher","first-page":"34570","DOI":"10.1038\/srep34570","volume":"6","author":"XG Li","year":"2016","unstructured":"Li XG, Ma N, Wang B, Li XQ, Mei SH, Zhao K, Wang YJ, Li W, Zhao ZG, Sun SS, Miao ZR (2016) The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease. Sci Rep 6:34570. https:\/\/doi.org\/10.1038\/srep34570","journal-title":"Sci Rep"},{"issue":"5","key":"4173_CR45","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1161\/strokeaha.115.012237","volume":"47","author":"C Gallego-Fabrega","year":"2016","unstructured":"Gallego-Fabrega C, Carrera C, Reny JL, Fontana P, Slowik A, Pera J, Pezzini A, Serrano-Heras G, Segura T, Mart\u00ed-F\u00e0bregas J, Mui\u00f1o E, Cullell N, Montaner J, Krupinski J, Fernandez-Cadenas I (2016) TRAF3 Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke. Stroke 47(5):1180\u20131186. https:\/\/doi.org\/10.1161\/strokeaha.115.012237","journal-title":"Stroke"},{"issue":"2","key":"4173_CR46","doi-asserted-by":"publisher","first-page":"100093","DOI":"10.1016\/j.rpth.2023.100093","volume":"7","author":"PY Song","year":"2023","unstructured":"Song PY, Li MP, Peng LM, Chen XP (2023) CD80 DNA methylation and single-nucleotide polymorphism associated with clopidogrel response: a whole-genome DNA methylation analysis in acute coronary syndrome. Res Pract Thromb Haemost 7(2):100093. https:\/\/doi.org\/10.1016\/j.rpth.2023.100093","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"4173_CR47","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1159\/000524416","volume":"51","author":"D Li","year":"2022","unstructured":"Li D, Ling X, Li X, Wei H, Zhao Z, Li X, Ma N (2022) Association between GNAQ Gene DNA Methylation and Vascular Recurrence in Patients with Acute Ischemic Stroke or Transient Ischemic Attack. Cerebrovasc Dis 51(6):712\u2013721. https:\/\/doi.org\/10.1159\/000524416","journal-title":"Cerebrovasc Dis"},{"issue":"5","key":"4173_CR48","doi-asserted-by":"publisher","first-page":"e22867","DOI":"10.1002\/jcla.22867","volume":"33","author":"J Su","year":"2019","unstructured":"Su J, Li J, Yu Q, Xu X, Wang J, Yang J, Li X, Chen X (2019) Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease. J Clin Lab Anal 33(5):e22867. https:\/\/doi.org\/10.1002\/jcla.22867","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"4173_CR49","doi-asserted-by":"publisher","first-page":"e23040","DOI":"10.1002\/jcla.23040","volume":"34","author":"J Su","year":"2020","unstructured":"Su J, Zheng N, Li Z, Huangfu N, Mei L, Xu X, Zhang L, Chen X (2020) Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients. J Clin Lab Anal 34(2):e23040. https:\/\/doi.org\/10.1002\/jcla.23040","journal-title":"J Clin Lab Anal"},{"issue":"21","key":"4173_CR50","doi-asserted-by":"publisher","first-page":"e021129","DOI":"10.1161\/jaha.121.021129","volume":"10","author":"YL Liu","year":"2021","unstructured":"Liu YL, Hu XL, Song PY, Li H, Li MP, Du YX, Li MY, Ma QL, Peng LM, Song MY, Chen XP (2021) Influence of GAS5\/MicroRNA-223-3p\/P2Y12 Axis on Clopidogrel Response in Coronary Artery Disease. J Am Heart Assoc 10(21):e021129. https:\/\/doi.org\/10.1161\/jaha.121.021129","journal-title":"J Am Heart Assoc"},{"key":"4173_CR51","doi-asserted-by":"publisher","first-page":"9322188","DOI":"10.1155\/2023\/9322188","volume":"2023","author":"H Cheng","year":"2023","unstructured":"Cheng H, Yang M, Hao J, Chen K, Tan Q, He S, Mao F, Yang M, Lin Y, Yang J (2023) Lower Plasma miR-223 Level Is Associated with Clopidogrel Resistance in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. J Interv Cardiol 2023:9322188. https:\/\/doi.org\/10.1155\/2023\/9322188","journal-title":"J Interv Cardiol"},{"issue":"6","key":"4173_CR52","doi-asserted-by":"publisher","first-page":"300060521101620","DOI":"10.1177\/03000605211016209","volume":"49","author":"X Li","year":"2021","unstructured":"Li X, Yao Q, Cui H, Yang J, Wu N, Liu Y, Zhou Y, Zhang Y, Su J, Xia Y, Chen X (2021) MiR-223 or miR-126 predicts resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction. J Int Med Res 49(6):3000605211016209. https:\/\/doi.org\/10.1177\/03000605211016209","journal-title":"J Int Med Res"},{"key":"4173_CR53","doi-asserted-by":"publisher","unstructured":"Wang DL, Li X, Wang RN, Sun Y, Xia XS, Tian WJ, Wang L (2022) A study of microRNA-223 in evaluating platelet reactivity in patients with acute ischemic stroke. J Physiol Pharmacol 73(1). https:\/\/doi.org\/10.26402\/jpp.2022.1.11","DOI":"10.26402\/jpp.2022.1.11"},{"key":"4173_CR54","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2147\/pgpm.S324612","volume":"14","author":"E Rytkin","year":"2021","unstructured":"Rytkin E, Mirzaev K, Bure I, Akmalova K, Abdullaev S, Kachanova A, Smirnov V, Grishina E, Lyakhova N, Aleshkovich E, Saribekian A, Andreev D, Shabunin A, Sychev D (2021) MicroRNAs as Novel Biomarkers for P2Y12 - Inhibitors Resistance Prediction. Pharmgenomics Pers Med 14:1575\u20131582. https:\/\/doi.org\/10.2147\/pgpm.S324612","journal-title":"Pharmgenomics Pers Med"},{"issue":"2","key":"4173_CR55","doi-asserted-by":"publisher","first-page":"e00751","DOI":"10.1002\/prp2.751","volume":"9","author":"S Lin","year":"2021","unstructured":"Lin S, Xu X, Hu H, Cheng J, Chen R, Hu Y, Chen X (2021) The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance. Pharmacol Res Perspect 9(2):e00751. https:\/\/doi.org\/10.1002\/prp2.751","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"4173_CR56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000517811","volume":"145","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhu F, Luo Y, Liao J, Cao J, Xue T (2022) Platelet miR-107 Participates in Clopidogrel Resistance after PCI Treatment by Regulating P2Y12. Acta Haematol 145(1):46\u201353. https:\/\/doi.org\/10.1159\/000517811","journal-title":"Acta Haematol"},{"key":"4173_CR57","doi-asserted-by":"publisher","first-page":"1078722","DOI":"10.3389\/fphar.2022.1078722","volume":"13","author":"TL Krammer","year":"2022","unstructured":"Krammer TL, Kollars M, Kyrle PA, Hackl M, Eichinger S, Traby L (2022) Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects. Front Pharmacol 13:1078722. https:\/\/doi.org\/10.3389\/fphar.2022.1078722","journal-title":"Front Pharmacol"},{"key":"4173_CR58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fgene.2013.00094","volume":"4","author":"MB Kirschner","year":"2013","unstructured":"Kirschner MB, Edelman JJ, Kao SC, Vallely MP, van Zandwijk N, Reid G (2013) The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Front Genet 4:94. https:\/\/doi.org\/10.3389\/fgene.2013.00094","journal-title":"Front Genet"},{"issue":"4","key":"4173_CR59","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1080\/09537104.2018.1457781","volume":"30","author":"M Zhou","year":"2019","unstructured":"Zhou M, Gao M, Luo Y, Gui R, Ji H (2019) Long non-coding RNA metallothionein 1 pseudogene 3 promotes p2y12 expression by sponging miR-126 to activate platelet in diabetic animal model. Platelets 30(4):452\u2013459. https:\/\/doi.org\/10.1080\/09537104.2018.1457781","journal-title":"Platelets"},{"key":"4173_CR60","doi-asserted-by":"publisher","first-page":"177156","DOI":"10.1016\/j.ejphar.2024.177156","volume":"986","author":"H Xu","year":"2025","unstructured":"Xu H, Su J, Chen X, Li J, Li Z, Zheng N, Yu R, Li X, Song Y, Li J, Xu F, Li C, Fei X, Du W, Yu Q (2025) Identification of hsa_circ_0076957 and miR-4512-targeted COL19A1 as regulators in clopidogrel resistance among stable coronary heart disease patients through comprehensive circRNA and miRNA analysis. Eur J Pharmacol 986:177156. https:\/\/doi.org\/10.1016\/j.ejphar.2024.177156","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4173_CR61","doi-asserted-by":"publisher","first-page":"20240899","DOI":"10.1515\/med-2024-0899","volume":"19","author":"Q Tan","year":"2024","unstructured":"Tan Q, Yang L, Yuan S, Zheng D, Lin Y, Chen K, He Y, Chen S, Hao J, Dai J, He S, Mao F, Leng X, Jiang H, Yang J (2024) METTL3-mediated methylation of CYP2C19 mRNA may aggravate clopidogrel resistance in ischemic stroke patients. Open Med (Wars) 19(1):20240899. https:\/\/doi.org\/10.1515\/med-2024-0899","journal-title":"Open Med (Wars)"},{"issue":"1","key":"4173_CR62","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13148-023-01602-w","volume":"15","author":"R Yu","year":"2023","unstructured":"Yu R, Yu Q, Li Z, Li J, Yang J, Hu Y, Zheng N, Li X, Song Y, Li J, Chen X, Du W, Su J (2023) Transcriptome-wide map of N6-methyladenosine (m6A) profiling in coronary artery disease (CAD) with clopidogrel resistance. Clin Epigenetics 15(1):194. https:\/\/doi.org\/10.1186\/s13148-023-01602-w","journal-title":"Clin Epigenetics"},{"issue":"2","key":"4173_CR63","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/nep3.44","volume":"2","author":"G Chen","year":"2024","unstructured":"Chen G, Du X, Cui J, Song J, Xiong M, Zeng X, Yang H, Xu K (2024) Role of gut microbiota in ischemic stroke: A narrative review of human and animal studies. Neuroprotection 2(2):120\u2013136. https:\/\/doi.org\/10.1002\/nep3.44","journal-title":"Neuroprotection"},{"issue":"1","key":"4173_CR64","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jtha.2022.10.010","volume":"21","author":"PX Ge","year":"2023","unstructured":"Ge PX, Tai T, Jiang LP, Ji JZ, Mi QY, Zhu T, Li YF, Xie HG (2023) Choline and trimethylamine N-oxide impair metabolic activation of and platelet response to clopidogrel through activation of the NOX\/ROS\/Nrf2\/CES1 pathway. J Thromb Haemost 21(1):117\u2013132. https:\/\/doi.org\/10.1016\/j.jtha.2022.10.010","journal-title":"J Thromb Haemost"},{"issue":"1","key":"4173_CR65","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00011-025-02128-y","volume":"74","author":"F Hajer","year":"2025","unstructured":"Hajer F, Malek A, Amani A, Rahma O, Khaldoun BH, Abdelhak F, Asma O, Amel HK, Saoussen C (2025) Beyond CYP2C19: inflammation and angiogenesis gene variants drive clopidogrel resistance in CAD patients. Inflamm Res 74(1):154. https:\/\/doi.org\/10.1007\/s00011-025-02128-y","journal-title":"Inflamm Res"},{"issue":"2","key":"4173_CR66","doi-asserted-by":"publisher","first-page":"e06251","DOI":"10.1016\/j.heliyon.2021.e06251","volume":"7","author":"W Al Awaida","year":"2021","unstructured":"Al Awaida W, Ahmed AA, Hamza AA, Amber KI, Al-Ameer HJ, Jarrar Y, Fatima G, Maslat AO, Gushchina Y, Al Bawareed O, Hadi NR (2021) Association of KDR rs1870377 genotype with clopidogrel resistance in patients with post percutaneous coronary intervention. Heliyon 7(2):e06251. https:\/\/doi.org\/10.1016\/j.heliyon.2021.e06251","journal-title":"Heliyon"},{"issue":"3","key":"4173_CR67","doi-asserted-by":"publisher","first-page":"202","DOI":"10.5455\/aim.2020.28.202-208","volume":"28","author":"AA Ahmed","year":"2020","unstructured":"Ahmed AA, Amber KI, Hadi NR (2020) The Impact of Kinase Insert Domain (KDR) Gene Polymorphism rs2305948 on Clopidogrel Resistance in Iraqi Patients Undergoing Elective Percutaneous Coronary Intervention (PCI). Acta Inf Med 28(3):202\u2013208. https:\/\/doi.org\/10.5455\/aim.2020.28.202-208","journal-title":"Acta Inf Med"},{"key":"4173_CR68","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.thromres.2018.04.017","volume":"167","author":"L Ying","year":"2018","unstructured":"Ying L, Wang F, Zhang J, Yang L, Gong X, Fan Y, Xu K, Li J, Lu Y, Mei L, Zhou Z, Li C (2018) Impact of hepatitis B virus (HBV) infection on platelet response to clopidogrel in patients undergoing coronary stent implantation. Thromb Res 167:119\u2013124. https:\/\/doi.org\/10.1016\/j.thromres.2018.04.017","journal-title":"Thromb Res"},{"issue":"2","key":"4173_CR69","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/clpt.2013.79","volume":"94","author":"KK Machavaram","year":"2013","unstructured":"Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, Wong S, Joshi A, Kenny JR (2013) A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther 94(2):260\u2013268. https:\/\/doi.org\/10.1038\/clpt.2013.79","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4173_CR70","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1054\/jcaf.2002.127773","volume":"8","author":"RF Frye","year":"2002","unstructured":"Frye RF, Schneider VM, Frye CS, Feldman AM (2002) Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 8(5):315\u2013319. https:\/\/doi.org\/10.1054\/jcaf.2002.127773","journal-title":"J Card Fail"},{"issue":"2","key":"4173_CR71","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40291-023-00691-w","volume":"28","author":"HG Xie","year":"2024","unstructured":"Xie HG, Jiang LP, Tai T, Ji JZ, Mi QY (2024) The Complement System and C4b-Binding Protein: A Focus on the Promise of C4BP\u03b1 as a Biomarker to Predict Clopidogrel Resistance. Mol Diagn Ther 28(2):189\u2013199. https:\/\/doi.org\/10.1007\/s40291-023-00691-w","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"4173_CR72","doi-asserted-by":"publisher","first-page":"E36","DOI":"10.1503\/cmaj.241581","volume":"198","author":"J Zhao","year":"2026","unstructured":"Zhao J, Tian X, Yang X, Xu Q, Xia X, Zhang Y, Xie X, Bath PM, Jing J, Wang Y, Meng X, Wang A (2026) Effect of insulin resistance on ticagrelor-versus clopidogrel-based dual antiplatelet therapy for secondary prevention of stroke in carriers of CYP2C19 loss-of-function mutations. CMAJ 198(2):E36\u2013e43. https:\/\/doi.org\/10.1503\/cmaj.241581","journal-title":"CMAJ"},{"issue":"9","key":"4173_CR73","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1097\/cm9.0000000000000210","volume":"132","author":"Q Ma","year":"2019","unstructured":"Ma Q, Chen GZ, Zhang YH, Zhang L, Huang LA (2019) Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events. Chin Med J (Engl) 132(9):1053\u20131062. https:\/\/doi.org\/10.1097\/cm9.0000000000000210","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"4173_CR74","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41397-018-0018-4","volume":"18","author":"Y Wu","year":"2018","unstructured":"Wu Y, Zhou Y, Pan Y, Zhao X, Liu L, Wang D, Wang C, Li H, Johnston SC, Meng X, Wang Y, Wang Y (2018) Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics J 18(6):713\u2013720. https:\/\/doi.org\/10.1038\/s41397-018-0018-4","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"4173_CR75","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2174\/1570161114666160714103148","volume":"14","author":"D Backovic","year":"2016","unstructured":"Backovic D, Ignjatovic S, Rakicevic L, Novkovic M, Kusic-Tisma J, Radojkovic D, Strugarevic E, Calija B, Radak D, Kovac M (2016) Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study. Curr Vasc Pharmacol 14(6):563\u2013569. https:\/\/doi.org\/10.2174\/1570161114666160714103148","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"4173_CR76","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1872312810666151117122841","volume":"10","author":"H Khalaf","year":"2016","unstructured":"Khalaf H, Al Meman AA, Rasool S (2016) Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome. Drug Metab Lett 10(1):65\u201370. https:\/\/doi.org\/10.2174\/1872312810666151117122841","journal-title":"Drug Metab Lett"},{"key":"4173_CR77","doi-asserted-by":"publisher","first-page":"107602962412807","DOI":"10.1177\/10760296241280711","volume":"30","author":"K Zhang","year":"2024","unstructured":"Zhang K, Li J, Li Y, Yan K, Zhu P, Tang X, Yuan D, Yang Y, Gao R, Yuan J, Zhao X (2024) Elevated High-Sensitivity C-Reactive Protein Level Enhances the Impact of Lipoprotein(a) on Platelet Reactivity in PCI Patients Treated with Clopidogrel. Clin Appl Thromb Hemost 30:10760296241280711. https:\/\/doi.org\/10.1177\/10760296241280711","journal-title":"Clin Appl Thromb Hemost"},{"key":"4173_CR78","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/pgpm.S165805","volume":"11","author":"DF Hernandez-Suarez","year":"2018","unstructured":"Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J (2018) Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. Pharmgenomics Pers Med 11:95\u2013106. https:\/\/doi.org\/10.2147\/pgpm.S165805","journal-title":"Pharmgenomics Pers Med"},{"key":"4173_CR79","doi-asserted-by":"publisher","unstructured":"Jastrzebska M, Lisman D, Szelepajlo A, Oledzki S, Chelstowski K, Clark JS, Siennicka A (2019) Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB\/IIIA receptor gene polymorphism. J Physiol Pharmacol 70(2). https:\/\/doi.org\/10.26402\/jpp.2019.2.01","DOI":"10.26402\/jpp.2019.2.01"},{"issue":"3 Vyp 2","key":"4173_CR80","doi-asserted-by":"publisher","first-page":"45","DOI":"10.17116\/jnevro201911903245","volume":"119","author":"DA Sychev","year":"2019","unstructured":"Sychev DA, Shprakh VV, Kitaeva EY, Mirzaev KB, Mickhalevich IM (2019) [Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova 119(3 Vyp 2):45\u201352. https:\/\/doi.org\/10.17116\/jnevro201911903245","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"6","key":"4173_CR81","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/fjc.0000000000000627","volume":"72","author":"BA Al-Husein","year":"2018","unstructured":"Al-Husein BA, Al-Azzam SI, Alzoubi KH, Khabour OF, Nusair MB, Alzayadeen S (2018) Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance. J Cardiovasc Pharmacol 72(6):296\u2013302. https:\/\/doi.org\/10.1097\/fjc.0000000000000627","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5\u20136","key":"4173_CR82","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000521721","volume":"107","author":"Z Xu","year":"2022","unstructured":"Xu Z, Chen L, Liu Y, Chen C, Sun Y, Miao Y, Wu T, Niu J, Wei J, Cao X (2022) Study on the Interaction between Deuterium Clopidogrel and Omeprazole. Pharmacology 107(5\u20136):308\u2013316. https:\/\/doi.org\/10.1159\/000521721","journal-title":"Pharmacology"},{"issue":"1","key":"4173_CR83","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41598-024-51682-8","volume":"14","author":"CC Chang","year":"2024","unstructured":"Chang CC, Chou YC, Chang JY, Sun CA (2024) Effects of treatment with clopidogrel with or without proton pump inhibitor omeprazole on the risk of ischemic stroke: a nationwide cohort study. Sci Rep 14(1):1686. https:\/\/doi.org\/10.1038\/s41598-024-51682-8","journal-title":"Sci Rep"},{"issue":"11","key":"4173_CR84","doi-asserted-by":"publisher","first-page":"814","DOI":"10.31083\/ph.2014.4642","volume":"69","author":"XQ Liu","year":"2014","unstructured":"Liu XQ, Lin S, Qiu LL, Lin L, Zhao YY, Xu HM, Zhang J, Zou JJ (2014) Association of the use of amlodipine with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention. Pharmazie 69(11):814\u2013817","journal-title":"Pharmazie"},{"issue":"3","key":"4173_CR85","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/clpt.2013.192","volume":"95","author":"MT Holmberg","year":"2014","unstructured":"Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M (2014) Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin Pharmacol Ther 95(3):307\u2013313. https:\/\/doi.org\/10.1038\/clpt.2013.192","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4173_CR86","doi-asserted-by":"publisher","first-page":"e0304800","DOI":"10.1371\/journal.pone.0304800","volume":"19","author":"ART Brand Kanters","year":"2024","unstructured":"Brand Kanters ART, Roozendaal NC, Parr NMJ, Pasterkamp G, Urbanus RT, Korporaal SJA, de Borst GJ (2024) Perioperative platelet reactivity over time in patients undergoing vascular surgery: An observational pilot study. PLoS ONE 19(6):e0304800. https:\/\/doi.org\/10.1371\/journal.pone.0304800","journal-title":"PLoS ONE"},{"issue":"2","key":"4173_CR87","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejvs.2016.04.019","volume":"52","author":"TC Leunissen","year":"2016","unstructured":"Leunissen TC, Peeters Weem SM, Urbanus RT, den Ruijter HM, Moll FL, Asselbergs FW, de Borst GJ (2016) High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values. Eur J Vasc Endovasc Surg 52(2):198\u2013204. https:\/\/doi.org\/10.1016\/j.ejvs.2016.04.019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"4173_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/nep3.70057","author":"G Zhu","year":"2026","unstructured":"Zhu G, Chen X, Huang X, Tan Q, Cao Q, Yang Y, Lin Y, Yang J (2026) Current status and future perspectives of platelet function-guided precision antiplatelet therapy for patients with cerebral infarction. Neuroprotection DOI. https:\/\/doi.org\/10.1002\/nep3.70057","journal-title":"Neuroprotection DOI"},{"issue":"1","key":"4173_CR89","doi-asserted-by":"publisher","first-page":"33765","DOI":"10.1038\/s41598-025-96338-3","volume":"15","author":"G Bharath","year":"2025","unstructured":"Bharath G, Preethi L, Suriyam Nagappan A, Kalpana SR, Christopher R, Munirajan AK (2025) Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India. Sci Rep 15(1):33765. https:\/\/doi.org\/10.1038\/s41598-025-96338-3","journal-title":"Sci Rep"},{"issue":"1","key":"4173_CR90","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12883-025-04252-y","volume":"25","author":"M Tang","year":"2025","unstructured":"Tang M, Li X, Zhong G, Dong Y, Wang T, Yang L, Lai X, Chen Y, Chen X, Zuo J, Xu J, Shi H, Diao F (2025) Predicting clopidogrel resistance in acute ischemic stroke patients: key clinical insights and a novel diagnostic nomogram. BMC Neurol 25(1):240. https:\/\/doi.org\/10.1186\/s12883-025-04252-y","journal-title":"BMC Neurol"},{"issue":"2","key":"4173_CR91","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jcin.2024.08.027","volume":"22","author":"S Patel","year":"2019","unstructured":"Angiolillo D, Galli M, Alexopoulos D et al (2024) International consensus statement on platelet function and genetic testing in percutaneous coronary intervention. J Am Coll Cardiol Intv 17(22):2639\u20132663. https:\/\/doi.org\/10.1016\/j.jcin.2024.08.027","journal-title":"Ann Indian Acad Neurol"},{"issue":"4","key":"4173_CR92","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/ehjcvp\/pvz045","volume":"6","author":"JP Lewis","year":"2020","unstructured":"Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, D\u00e9ry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR (2020) Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur Heart J Cardiovasc Pharmacother 6(4):203\u2013210. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz045","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"4173_CR93","doi-asserted-by":"publisher","first-page":"e0306445","DOI":"10.1371\/journal.pone.0306445","volume":"19","author":"O Echeverr\u00eda","year":"2024","unstructured":"Echeverr\u00eda O, Angulo-Aguado M, Vela R, Calder\u00f3n-Ospina C, Parra K, Contreras N, Morel A, Cabrera R, Restrepo C, Ram\u00edrez-Santana C, Ortega-Recalde O, Rojas-Quintana ME, Murcia L, Gaviria-Sabogal CC, Valero N, Fonseca-Mendoza DJ (2024) The polygenic implication of clopidogrel responsiveness: Insights from platelet reactivity analysis and next-generation sequencing. PLoS ONE 19(7):e0306445. https:\/\/doi.org\/10.1371\/journal.pone.0306445","journal-title":"PLoS ONE"},{"issue":"5","key":"4173_CR94","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"JJ Swen","year":"2011","unstructured":"Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ (2011) Pharmacogenetics: from bench to byte\u2013an update of guidelines. Clin Pharmacol Ther 89(5):662\u2013673. https:\/\/doi.org\/10.1038\/clpt.2011.34","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"4173_CR95","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jacep.2021.04.012","volume":"7","author":"DG Della Rocca","year":"2021","unstructured":"Della Rocca DG, Horton RP, Di Biase L, Gianni C, Trivedi C, Mohanty S, Anannab A, Magnocavallo M, Chen Q, Tarantino N, Bassiouny M, Lavalle C, Natale VN, Forleo GB, Del Prete A, Van Niekerk CJ, Al-Ahmad A, Burkhardt JD, Gallinghouse GJ, Sanchez JE, Lakkireddy D, Gibson DN, Natale A (2021) Incidence of Device-Related Thrombosis in Watchman Patients Undergoing a Genotype-Guided Antithrombotic Strategy. JACC Clin Electrophysiol 7(12):1533\u20131543. https:\/\/doi.org\/10.1016\/j.jacep.2021.04.012","journal-title":"JACC Clin Electrophysiol"},{"issue":"2","key":"4173_CR96","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","volume":"11","author":"LH Cavallari","year":"2018","unstructured":"Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA (2018) Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv 11(2):181\u2013191. https:\/\/doi.org\/10.1016\/j.jcin.2017.07.022","journal-title":"JACC Cardiovasc Interv"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04173-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04173-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04173-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:47:49Z","timestamp":1789454869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04173-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":96,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4173"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04173-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"246"}}